Pharmacotherapy For Child And Adolescent Psychiatric Disorders

The Second Edition of Pharmacotherapy for Child and Adolescent Psychiatric Disorders contains new and expanded chapters on combination therapy pharmacoepidemiology pharmacoeconomics current social, ethical, and legal issues surrounding the administration of psychostimulants and antidepressants to children and teenagers serotonin reuptake inhibitors and discusses techniques to select the most appropriate drug and dosing schedule methods to adjust safely and tailor medical treatments for children during various stages of growth and development the effect of psychoactive drugs on cardiac function Offering nearly 3000 contemporary references to facilitate further research, Pharmacotherapy for Child and Adolescent Psychiatric Disorders, Second Edition is a timely and authoritative guide suitable for psychiatrists, psychologists, pediatricians, pharmaceutical and behavioral scientists, clinical neurologists, primary care physicians, social workers, and graduate and medical school students in these disciplines.

The book covers an extensive range of psychotropic drugs and a number of adjunctive medications. Completely up-to-date, it has been written in accordance with the DSM-IV.

This book offers a comprehensive survey of the current state of knowledge in the field of neuro-psychopharmacology in childhood and adolescence. In the first part, the essentials of neuro-psychopharmacology are presented in order to provide a deeper understanding of the principles and particularities in the pharmacotherapy of children and adolescents. This part includes information on neurotransmitters and signal transduction pathways, molecular brain structures as targets for psychiatric drugs, characteristics of psychopharmacological therapy in children and adolescents, ontogenetic influences on pharmacokinetics and pharmacodynamics, and pharmacotherapy in the outpatient setting. The part on classes of psychiatric medications, which covers antidepressants, antipsychotics, anxiolytics and sedative-hypnotics, mood stabilizers, and psychostimulants and other drugs used in the treatment of attention-deficit/hyperactivity disorder, provides sufficient background material to better understand how psychoactive drugs work, and why, when, and for whom they should be used. For each drug within a class, information on its mechanisms of action, clinical pharmacology, indications, dosages, and cognate issues are reviewed. In the third part, the disorder-specific and symptom-oriented medication is described and discerningly evaluated from a practical point of view, providing physicians with precise instructions on how to proceed. Psychiatric Drugs in Children and Adolescents includes numerous tables, figures and illustrations and offers a valuable reference work for child and adolescent psychiatrists and psychotherapists, pediatricians, general practitioners, psychologists, and nursing staff, as well as teachers.

This is a quick-reference guide for psychiatrists, therapists, social workers, and other practitioners about each group of medications. This guide, which discusses the use of psychiatric drugs in patients under 18, accompanies the author team's complete book "Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disorders".; Clinical indications, dosage guidelines, side-effects, common drug interactions and most tables are retained and updated in this guide. the guide provides the reader with the practical guidelines to safely and effectively prescribe medication.

This is a quick-reference guide for psychiatrists, therapists, social workers, and other practitioners about each group of medications. This guide, which discusses the use of psychiatric drugs in patients under 18, accompanies the author team's complete book Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disorders.; Clinical indications, dosage guidelines, side-effects, common drug interactions and most tables are retained and updated in this guide. the guide provides the reader with the practical guidelines to safely and effectively prescribe medication.

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly.

It is clear that child and adolescent psychiatric disorders impose a heavy burden of suffering. Recent large-scale community epidemiological studies suggest that as many as 20% of children and adolescents in the general population may have clinically important mental disorders. These disorders are accompanied by associated impairments in various domains of the child's life, resulting in lowered life quality for the child and his or her family. In addition, for some conditions, the onset of the disorder in childhood heralds a lifetime of serious psychosocial disturbance for a significant subgroup of affected children. For instance, about 40% of children seen in clinic settings with conduct disorder in late childhood and early adolescence will have serious psychiatric disorders in adult life. Finally, the heavy burden of suffering of these conditions is indicated by the large amounts of both human and financial resources devoted to their assessment and treatment. There is a pressing need in the field for effective treatments (that is, those that have been shown to do more good than harm) that will result in a significant reduction in the burden of suffering resulting from these disorders. Further, these effective interventions must be readily available and acceptable to clini cians in the settings in which children with mental disorders (and their families) seek care. This book addresses an important need in the treatment field.